+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Overactive Bladder - Pipeline Review, H2 2019

  • ID: 4901331
  • Drug Pipelines
  • December 2019
  • 120 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aetas Pharma Co Ltd
  • Dare Bioscience Inc
  • Dong-A ST Co Ltd
  • J2H Biotech
  • Merck & Co Inc
  • Recordati SpA
  • MORE
Overactive Bladder - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2019, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 6, 7, 4, 1, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aetas Pharma Co Ltd
  • Dare Bioscience Inc
  • Dong-A ST Co Ltd
  • J2H Biotech
  • Merck & Co Inc
  • Recordati SpA
  • MORE
Introduction
Report Coverage
Overactive Bladder - Overview
Overactive Bladder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Overactive Bladder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Overactive Bladder - Companies Involved in Therapeutics Development
Aetas Pharma Co Ltd
Allergan Plc
Astellas Pharma Inc
Dare Bioscience Inc
DelNova Inc
Dompe Farmaceutici SpA
Dong-A ST Co Ltd
DongKoo Bio & Pharma Co Ltd
Evestra Inc
FemmePharma Global Healthcare Inc
Hydra Biosciences Inc
Ion Channel Innovations LLC
J2H Biotech
Kissei Pharmaceutical Co Ltd
KYORIN Holdings Inc
Kyorin Pharmaceutical Co Ltd
Medytox Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Outpost Medicine Ltd
Recordati SpA
Revance Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Taris Biomedical LLC
TheraVida Inc
Velicept Therapeutics Inc
Veru Inc
XuanZhu Pharma Co Ltd
Overactive Bladder - Drug Profiles
Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Overactive Bladder, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Overactive Bladder - Pipeline by Aetas Pharma Co Ltd, H2 2019
Overactive Bladder - Pipeline by Allergan Plc, H2 2019
Overactive Bladder - Pipeline by Astellas Pharma Inc, H2 2019
Overactive Bladder - Dormant Projects, H2 2019
Overactive Bladder - Dormant Projects, H2 2019 (Contd..1), H2 2019
Overactive Bladder - Dormant Projects, H2 2019 (Contd..2), H2 2019
Overactive Bladder - Dormant Projects, H2 2019 (Contd..3), H2 2019
Overactive Bladder - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Overactive Bladder, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aetas Pharma Co Ltd
  • Allergan Plc
  • Astellas Pharma Inc
  • Dare Bioscience Inc
  • DelNova Inc
  • Dompe Farmaceutici SpA
  • Dong-A ST Co Ltd
  • DongKoo Bio & Pharma Co Ltd
  • Evestra Inc
  • FemmePharma Global Healthcare Inc
  • Hydra Biosciences Inc
  • Ion Channel Innovations LLC
  • J2H Biotech
  • Kissei Pharmaceutical Co Ltd
  • KYORIN Holdings Inc
  • Kyorin Pharmaceutical Co Ltd
  • Medytox Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • Outpost Medicine Ltd
  • Recordati SpA
  • Revance Therapeutics Inc
  • Taiho Pharmaceutical Co Ltd
  • Taris Biomedical LLC
  • TheraVida Inc
  • Velicept Therapeutics Inc
  • Veru Inc
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll